Unknown

Dataset Information

0

Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration.


ABSTRACT: Since therapeutic peptides and oligonucleotides are gathering interests as active pharmaceutical ingredients (APIs), nanoparticulate drug delivery systems are becoming of great importance. Thereby, the possibility to design drug delivery systems according to the therapeutic needs of APIs enhances clinical implementation. Over the last years, the focus of our group was laid on protamine-oligonucleotide-nanoparticles (so called proticles), however, the possibility to modify the size, zeta potential or loading efficiencies was limited. Therefore, at the present study we integrated a stepwise addition of protamine (titration) into the formation process of proticles loaded with the angiogenic neuropeptide secretoneurin (SN). A particle size around 130 nm was determined when proticles were assembled by the commonly used protamine addition at once. Through application of the protamine titration process it was possible to modify and adjust the particle size between approx. 120 and 1200 nm (dependent on mass ratio) without influencing the SN loading capacity. Dynamic light scattering pointed out that the difference in particle size was most probably the result of a secondary aggregation. Initially-formed particles of early stages in the titration process aggregated towards bigger assemblies. Atomic-force-microscopy images also revealed differences in morphology along with different particle size. In contrast, the SN loading was only influenced by the applied mass ratio, where a slight saturation effect was observable. Up to 65% of deployed SN could be imbedded into the proticle matrix. An in-vivo biodistribution study (i.m.) showed a retarded distribution of SN from the site of injection after the application of a SN-proticle formulation. Further, it was demonstrated that SN loaded proticles can be successfully freeze-dried and resuspended afterwards. To conclude, the integration of the protamine titration process offers new possibilities for the formulation of proticles in order to address key parameters of drug delivery systems as size, API loading or modified drug release.

SUBMITTER: Scheicher B 

PROVIDER: S-EPMC5102448 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration.

Scheicher Bernhard B   Lorenzer Cornelia C   Gegenbauer Katrin K   Partlic Julia J   Andreae Fritz F   Kirsch Alexander H AH   Rosenkranz Alexander R AR   Werzer Oliver O   Zimmer Andreas A  

PloS one 20161109 11


Since therapeutic peptides and oligonucleotides are gathering interests as active pharmaceutical ingredients (APIs), nanoparticulate drug delivery systems are becoming of great importance. Thereby, the possibility to design drug delivery systems according to the therapeutic needs of APIs enhances clinical implementation. Over the last years, the focus of our group was laid on protamine-oligonucleotide-nanoparticles (so called proticles), however, the possibility to modify the size, zeta potentia  ...[more]

Similar Datasets

| S-EPMC2739987 | biostudies-literature
| S-EPMC4632989 | biostudies-literature
| S-EPMC3088165 | biostudies-literature
| S-EPMC3898745 | biostudies-literature
| S-EPMC7558620 | biostudies-literature
| S-EPMC6209253 | biostudies-literature
| S-EPMC9730763 | biostudies-literature
| S-EPMC8472779 | biostudies-literature
| S-EPMC3973031 | biostudies-literature
| S-EPMC5504013 | biostudies-literature